≡

Multiplex Assay Kit for Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay)

HGPRT; HGPRTase; HPRT; Lesch-Nyhan Syndrome; Hypoxanthine-guanine phosphoribosyltransferase

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-92 87
EDTA plasma(n=5) 98-105 101
heparin plasma(n=5) 82-90 86
sodium citrate plasma(n=5) 86-101 96

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 91-99% 85-101% 80-102% 94-104%
EDTA plasma(n=5) 83-95% 93-102% 88-101% 85-92%
heparin plasma(n=5) 98-105% 83-93% 95-102% 86-105%
sodium citrate plasma(n=5) 92-101% 91-102% 86-93% 84-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:HPRT1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
J Crohns Colitis. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C. Pubmed:25518051
J Crohns Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin C PubMed: 25518051
Molecular Biology Reports Increased ENT2 Expression and Its Association With Altered Purine Metabolism in Different Stages of Colorectal Cancer Cell Lines
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA717Hu01 Recombinant Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Positive Control; Immunogen; SDS-PAGE; WB.
PAA717Hu01 Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) WB; IHC; ICC; IP.
FAA717Hu01 Anti-Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Polyclonal Antibody Flow cytometry.
MAA717Hu22 Monoclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) WB; IHC; ICC; IP.
SEA717Hu ELISA Kit for Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA717Hu Multiplex Assay Kit for Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.